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1. Antibiotics and antibiotic resistance in the pre-antibiotic era
Antibiotics are known to exist in the history of mankind since ancient times. They can be 
traced back to as early as 350–550 CE, when scientists found traces of tetracycline inhuman 
skeletal remains of ancient Sudanese Nuba [1]. This has led to the speculation that the diet 
of this population contained tetracycline. Even the red soils of Jordon which have been used 
since time immemorial to treat wounds have been shown to contain Actinomycete bacteria 
which produced actinomycin [2]. Antimicrobial activity is also present in many of the herbs 
used in traditional Indian Ayurvedic and Chinese medicines.
Antibiotics have saved countless lives, and at one point of time, we imagined that infectious 
diseases were conquered. Most of the advances of modern medicine including state of art sur-
geries and management of neutropenic, transplant and cancer patients are based on the use 
of effective broad-spectrum antibiotics. Thanks to the way we have handled these precious 
resources for treatment of variety of infectious diseases. However, we found to our dismay 
subsequently that we are stepping into the post-antibiotic era.
Antibiotic resistance genes have been present in nature long before the modern antibiotic era 
began. Some of the serine and metallo-beta-lactamases originated more than 2 million years 
ago [3]. It seems prudent to assume that the ancient bacteria had defence mechanisms (such as 
antibiotic altering enzymes or efflux pumps) to protect themselves from high antibiotic con-
centrations. Hence, the biosynthetic gene cluster that makes the “antibiotic” must also contain 
genes which confer “resistance” to these antibiotics, and many aspects of the resistome (col-
lection of all AMR genes in a specific bacteria or ecological niche) might have developed much 
before these antibiotics became prevalent in clinical practice.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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2. Modern antibiotic era
Modern antibiotic era began in 1904–1910 with Paul Ehrlich and Alexander Fleming [4, 5]. 
Initially, it was limited to the discovery of chemicals like inorganic mercury salts and organo-
arsenic compounds to treat syphilis. It was Paul Ehrlich who introduced the systemic screen-
ing approach that is the cornerstone of modern drug research trials [4]. Paul Ehrlich and his 
team synthesised hundreds of organo-arsenic derivatives of a very toxic drug Atoxyl and 
tested them in rabbits infected with syphilis. This approach led to the discovery of Salvarsan 
and later to a sulfa drug (Prontosil). The serendipitous discovery of penicillin by Alexander 
Fleming in 1928 changed the history of infectious diseases [5]. It was Florey and Chain who 
led the pathway for purification of penicillin and later to its mass production [6]. Interestingly 
enough, Fleming was the one who sounded the warning bells regarding the development of 
resistance to the penicillin, if not used properly. So, in a nutshell, discovery of the first three 
antimicrobials, Salvarsan, Prontosil and penicillin paved the pathway for the discovery of 
newer antibiotics in future.
The golden era of discovery of newer antibiotics continued and lasted till 1970s when most of 
the major classes like tetracyclines, methicillin, gentamicin, etc. were discovered [7]. This was 
followed by apparent absence of newer drug discovery with occasional antibiotic making an 
appearance here and there. Simultaneously, we made each newly discovered antibiotic inef-
fective after its launch by extensive use and misuse for trivial illnesses. The prime example of 
this is the fluoroquinolone, ciprofloxacin [8]. It was one of the most active, broad-spectrum 
antibiotics which had minimum side effects and a very good bioavailability upon oral use and 
soon became a drug of choice for many infections. Its extensive usage for gastroenteritis and 
respiratory infections, which were mostly viral in origin, led to the development of high level 
of resistance especially in developing countries.
3. Antibiotic resistance: origin and current status
The first concern regarding antimicrobial resistance appeared with the observation of pen-
icillin resistant Staphylococcus in 1940 [7]. Initial few observations suggested that bacteria 
could destroy the drug by enzymatic degradation. Shortly thereafter, penicillin resistance 
became a substantial clinical problem. The first case of methicillin-resistant Staphylococcus 
aureus (MRSA) was identified in the United Kingdom in 1962 and in the United States 
in 1968 [9, 10]. In reality, this is true for many other pathogenic bacteria, including the 
Enterobacteriaceae, which have become resistant not only to the original penicillin but also 
to semisynthetic penicillins, cephalosporins and newer carbapenems [11]. Details about 
the development of the resistance in different classes of antibiotics are shown in the time-
line (Figure 1) [7]. Antimicrobial resistance often occurs through various mechanisms such 
as inhibition of cell wall synthesis, nucleic acid synthesis, ribosome function, protein syn-
thesis, folate metabolism and cell membrane function. The target can be (i) modified, as in 
the case of acetylation of aminoglycosides, (ii) destroyed (as the β-lactam antibiotics by the 
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action of β-lactamases) and (iii) pumped out from the cell as in efflux pump mechanisms 
of resistance [12].
Unfortunately, true burden of antimicrobial resistance (AMR) remains unknown. There are 
many hindrances in estimating the burden of AMR. Incongruent data is available from public 
and private sectors; data are often not collected properly and contain little information of 
patient follow up. These problems are intensified in low- and middle-socioeconomic coun-
tries due to problems of inadequate surveillance, poor laboratory infrastructure and limited 
access to the crucial antimicrobials. According to a study from Vietnam and Thailand, preva-
lence of stool carriage of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli 
was 51.0 and 69.3%, respectively [13]. There is also an increasing prevalence of MDR Gram-
positive bacteria. Another study in Thailand and Indonesia showed that prevalence of MRSA 
carriage is around 8% in admitted patients [14, 15]. Similar or worse situation exists in other 
Asian countries including China, Pakistan, Bangladesh and India. Antimicrobial resistance 
is a global issue. Resistance genes spread throughout the world as recent database lists the 
existence of more than 20,000 potential resistance genes (r genes) of nearly 400 different types, 
predicted from available sequences [16]. It is difficult to estimate the exact AMR burden due to 
the lack of comprehensive and uniform data. Gram-negative bacteria possessing the capabili-
ties of producing extended-spectrum beta-lactamases (ESBL), AmpC beta-lactamases and car-
bapenemases have emerged as a therapeutic challenge for medical fraternity [17]. Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeru-
ginosa, and Enterobacter species have been classified into a group known as “ESKAPE” due to 
their ability to escape the action of antimicrobials [18]. Multiple mechanisms of antimicrobial 
resistance have been acquired by carbapenem-resistant Enterobacteriaceae (CRE), P. aerugi-
nosa and A. Baumannii resulting in enhanced morbidity and mortality [19–23]. In the 1990s, 
Figure 1. Timeline showing antibiotic development and antimicrobial resistance.
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emergence of ESBLs among different microorganisms on global level led to widespread and 
increased use of carbapenems giving rise to emergence of pandemic CRE [24]. The Centers for 
Disease Control and Prevention has categorised CRE as urgent and ESBL-producing Gram-
negative bacteria as serious antibiotic threats in the USA [10].
4. The scare and complexity of antibiotic resistance
The scale, to which antibiotic resistance has become a challenge in the treatment of the mod-
ern medicine, is scary to say the least. Every year, around 25,000 patients die of the infec-
tion with multidrug-resistant bacteria alone in the European Union [25]. In the United States 
alone, nearly 90,000 people die of hospital-acquired infections [26]. According to Jim O’Neill, 
>700,000 people die across the globe every year due to infections caused by multidrug-resis-
tant organisms [27]. In this study, it was predicted that by 2050, more than 10 million people 
will die because of multidrug-resistant bugs. Huge economic losses are also expected, leading 
to reduction of 2–3.5% in GDP; livestock production will fall by 3–8%, costing the world up 
to $100 trillion [27]. Developing countries in Africa and South Asia will be the worst affected.
AMR is not only a problem of human medicine but also an ecological problem. Microbes have 
proved not only smarter than humans in developing new arsenal but also have armies in the 
form of biofilms. It looks like humans may be losing the arms race to bacteria, and the advent 
of the post-antibiotic era is imminent.
5. Causes of the antibiotic resistance crisis
5.1. Overuse
Antibiotic consumption is the single most important risk factor for emergence and spread 
of resistant bacterial strains. In many countries including India, antibiotics are easily avail-
able over the counter even without a prescription [28]. Moreover, antibiotics are plentiful 
and cheap also. This non-prescription use of drugs varies from 19 to 90% in various countries 
outside the United States and Europe, which is a matter of serious concern [29]. The prob-
lem has been compounded by the online purchase of these products, which further facilitate 
the self-medication. Some surveys reported that patients often do not know that they were 
prescribed an antimicrobial and the true proportion of patients using antimicrobials is prob-
ably higher than the reported [30, 31]. On the other hand, there are instances where patients 
demand antibiotics from their clinicians.
5.2. Inappropriate prescriptions
Incorrectly prescribed antibiotics contribute majorly to the burden of resistant bacteria. 
Several studies have observed that indication, choice of the antibiotics and duration of 
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treatment are incorrect in almost 30–50% of cases [32, 33]. Extensive usage occurs in ICUs 
and high-dependency units, and there too approximately, 30–60% of the usage is unneces-
sary or incorrect [33]. Studies from pharmacies of Vietnam show that 90% of antimicrobials 
are sold without a proper prescription [34]. Upper respiratory tract infections (URTI) are 
good example, for which antimicrobial are commonly prescribed over the counter. This 
illustrates the overuse of antimicrobials for a condition that is often self-limiting and gen-
erally of viral aetiology. Suboptimal doses of any antibiotic further promote the genetic 
alterations as well as mutagenesis in the bacteria which lead to the development of multi-
drug resistance in them.
5.3. Extensive use in livestock sector
Antibiotics are widely used as growth promoters and to prevent infections in the live-
stock sector. In the United States alone, an estimated 80% of the sold antibiotics are used 
in farm animals [7]. In 2010, India was one of the world’s largest consumers of antibiot-
ics in the veterinary sector [35]. The resistant bacteria reach the consumers through food 
animal products, mainly meat. These bacteria constitute large pools of AMR genes that 
can be transferred to humans and pathogenic bacteria by natural horizontal gene transfer 
mechanisms. These bacteria, although some may only be transient and do not colonise 
the intestinal tract, reside long enough to interact with the host microbiota and may pos-
sibly acquire or release genes. They can also act as opportunistic pathogens in susceptible 
hosts and probably play a key role in the evolution and dissemination of AMR. The use of 
antibiotics in food not only leads to the emergence and spread of resistant bacteria but also 
can be hazardous to many types of nontargeted environmental microorganisms. High con-
centrations of therapeutic antibiotics tend to be lethal to most bacterial strains leaving little 
opportunity for selection of subpopulations that have low or intermediate resistant traits. 
On the other hand, low levels of antibiotics in environment like soil, water and sewage 
become grounds for the selection of resistant microorganisms leading to the development 
of resistant gene pool or resistome [7, 12].
5.4. Availability of few new antibiotics
Investment in antibiotic development research is no longer considered as an economically 
wise decision for pharmaceutical companies [36]. According to a study conducted in London, 
it was calculated that the net present value (NPV) of new antibiotics is only about $50 million, 
compared to approximately $1 billion for a drug used to treat a neuromuscular disease [37].
Other reasons include low cost of antibiotics, regulatory barriers and tendency to save the 
new drug for serious infections. In spite of global warnings issued by many agencies, very few 
new drug discoveries fail to keep pace with worsening resistance scenario. As declared by the 
CDC in 2013, the human race is moving into a new era of infectious disease: the post-antibiotic 
period [38]. Here are few examples of the MDR organisms which are considered a substantial 
threat to the humankind. They have been divided as “urgent,” “serious” or “concerning” by 
CDC [24, 39] (Figure 2).
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6. Solutions: do we have any?
There is an urgent need to strategize to save the existing antimicrobials. We can perform that 
by following means to improve the existing ones, discover novel antibiotics, dig up the old so-
called toxic compounds, scale up antibiotic stewardship, use inter-sectorial multidisciplinary 
approaches, educate the public and clinician’s alike and reduce the antibiotics in livestock and 
agriculture to name a few [12].
6.1. New targets/approaches
Soil and marine environments appear to be rich ecological niches to discover new agents and 
so do the plants and animals. Co-trimoxazole was a perfect example of targeting two enzymes 
in a metabolic pathway producing synergism. Compounds can be synthesised artificially to 
target more than one mechanism. There is important role of whole genome sequencing and 
metagenomics to find the new targets.
Figure 2. Urgent, concerning and serious threats with respect to development of antimicrobial resistance.
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We hope that novel hitherto unknown mechanisms of antibiotic resistance will be revealed 
which can be exploited to find new targets. The drugs targeting anti-virulence mechanisms 
are an attractive strategy and have shown some promising results. Other interesting approach 
may be to target/alter untapped metabolic pathways like fatty acid synthesis, proton motive 
force, quorum sensing, signal transduction, efflux pumps, etc. [12]. Many of such compounds 
are currently in experimental stages.
6.2. Repurposing of compounds
Some of the compounds are already approved by FDA for treatment of metabolic disorders 
and cancers also have antimicrobial properties and can be repurposed, e.g., the compound 
BPH-652 that inhibits squalene synthase involved in cholesterol biosynthesis and also inhib-
its dehydrosqualene synthase involved in virulence in Staphylococcus aureus, hence a good 
candidate for Methicillin-resistant Staphylococcus aureus (MRSA) [12].
6.3. Considering conventional drugs
The drugs used in the past, which have been revived and now are used to treat the infections 
caused by Gram-negative bacteria, include colistin, fosfomycin, temocillin and rifampicin [17].
6.4. Combination therapy
Finding a suitable antimicrobial treatment option for some of the highly drug-resistant bac-
teria can be really daunting, and many times, clinicians resort to using combinations without 
data pertaining to their efficacy. The main drugs in these combinations are polymyxins and 
tigecycline; however, additional drugs comprise carbapenems, tigecycline, fosfomycin, ami-
noglycosides, and rifampicin [17] where data on randomised control trials of these drugs is 
also lacking. The factors which need to be taken into account before an appropriate combina-
tion is used includes the targeted organism and its susceptibility profile, co-morbidities pres-
ent in the patient and the site of the infection. More studies including pharmacokinetic and 
pharmacodynamics studies are required to find the ideal combinations [40].
6.5. Phage therapy
Phages have the advantage of high specificity for their hosts without any notable adverse 
effects. They were historically in use in Europe for treatment of bacterial infections such as 
skin/wound infections, urinary tract infections, ear infections and even osteomyelitis [41]. 
New interest has been generated in phage therapy, and it may turn out to be a useful adjunct 
to antibiotics. Coupling antibiotics with phages or inhibitors of enzymes appears to be an 
attractive strategy which may succeed in many cases [41].
7. Prevention of further spread of AMR
The extent to which AMR has spread is due to the selective pressure provided by extensive anti-
biotic consumption and usage. Strategies to curtail the human use of antibiotic include antibiotic 
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stewardship, public awareness to avoid self-medication, use of antibiotics in therapeutic doses 
and for appropriate length of time and education and counselling to patients not to pressurise 
the clinician into prescribing antibiotics for trivial illnesses. Development of new rapid diagnos-
tic point of care tests will inform the clinician not to use antibiotics in the viral infections.
7.1. Regulation in human as well livestock sector
Though a sticky and complex issue, regulation of unprescribed antibiotics is essential espe-
cially in developing countries. There should be the rule of “prescription-only medicines” sim-
ilar to various international guidelines [42]. In the veterinary and agriculture set-up, antibiotic 
usage is linked to economic gains. Scandinavian countries set up a good example to follow by 
not using antibiotics as growth promoters, and they do have the least AMR issues [43].
7.2. Antibiotic stewardship
Antimicrobial stewardship refers to “The optimal selection, dosage, and duration of anti-
microbial treatment that results in the best clinical outcome for the treatment or preven-
tion of infection, with minimal toxicity to the patient and minimal impact on subsequent 
resistance” [44]. Hence, antimicrobial stewardship basically aims at helping each patient 
receive the appropriate treatment without adverse effects of antibiotic use. These pro-
grammes are beneficial in reducing treatment failures, decreasing health-care associated 
infections and also reducing antibiotic resistance while proving economically beneficial 
to the hospital.
7.3. Connecting human, animal and environmental health: One Health Approach
In 2003, in an interview, a journalist used the word “One Health” by saying that “Human or 
livestock or wildlife health can’t be discussed in isolation anymore-there is just one health” 
[45]. Since then “One Health” concept has gained more recognition in the public health and 
animal health communities. “One Health” is a collaborative approach among various sec-
tors and disciplines to achieve optimal health outcomes emphasising the relation between 
humans, animals, plants and environment shared by them [46]. This is the need of the hour 
because many diseases are zoonotic in nature, and microbes harbouring drug-resistant genes 
have no barriers. Now the WHO and CDC have also adopted this approach.
8. Conclusions
The AMR is marching globally and threatens to undo the extraordinary advancements 
achieved in human medicine. Coordinated efforts are required across the globe to manage 
this great crisis. It is time we learn from our mistakes and gather our act together to outsmart 
the bacteria. All said and done, microbes do have an evolutionary advantage of nearly 4 bil-
lion years and have learnt to survive the onslaught of antibiotics. We can learn from them by 
using the sophisticated molecular approaches we have. Antimicrobial resistance is not only a 
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human health problem but is an ecological challenge as well. It is up to the human race to take 
up this challenge and save the world from this menace.
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